Her $0 Medicare Plan Was Perfect Until the Cancer Diagnosis

A 68-year-old retiree picked the $0-premium Medicare Advantage plan three years ago because she was healthy, her doctors were in-network, and the gym membership was a nice extra. In June she was diagnosed with stage III breast cancer. The first oncologist she wanted was out-of-network. The second was in-network but needed prior authorization for the PET scan, then for the chemo regimen, then for the targeted therapy. Her plan’s in-network out-of-pocket maximum is the number she remembered from the brochure. The number she will actually pay is higher.

This is the trade-off Medicare Advantage hides in plain sight. The premium is real. So is the cap. But the cap covers less than most enrollees expect, and the access limits are what bite in a sick year. With roughly 35.5 million Americans now enrolled in Medicare Advantage, representing about 55% of all eligible Medicare beneficiaries, the stakes of that trade-off have never been larger. If you are healthy and your doctors are in-network, none of this changes your math. If you have just been handed a serious diagnosis, keep reading.

The advertised cap covers less than enrollees expect

Two things sit outside a Medicare Advantage plan’s advertised in-network out-of-pocket maximum, and a cancer year hits both.

The first is Part D drug spending. The Inflation Reduction Act capped annual out-of-pocket Part D costs at $2,100 in 2026, which is a genuine protection. But that cap runs parallel to the medical cap, not inside it. The average Medicare Advantage in-network out-of-pocket limit is $5,421 in 2026, according to KFF. Add the drug cap and a seriously ill enrollee can face roughly $7,500 in combined Part A, Part B, and Part D exposure before a single out-of-network bill arrives. About 9% of enrollees, roughly 1.8 million people, are in plans set right at the $9,250 federal ceiling, where the gap between the advertised cap and the worst-case bill is widest.

The second is out-of-network care. The federal in-network MOOP ceiling is $9,250 for 2026. For PPO plans that cover out-of-network care, the federal combined ceiling rises to $13,900, with average PPO plans landing around $9,825. HMO plans generally do not cover out-of-network care outside of emergencies, which can turn a referral to an NCI-designated cancer center into a full-price bill rather than a cost-shared one. The brochure rarely shows those two numbers side by side.

The non-dollar catch

Prior authorization is where the real friction lives. Imaging, infusion drugs, surgical procedures, skilled nursing transfers, and durable medical equipment routinely require plan approval before the claim will pay. A denial is appealable, but an appeal takes time, and in oncology, time is the variable that matters most.

The 2026 CMS prior authorization rule (CMS-0057-F) requires plans to decide standard requests within seven calendar days and urgent requests within 72 hours, with written explanations for any denial. These are meaningful consumer protections. They do not eliminate prior authorization; they add guardrails around it. Notably, CMS chose to defer a key clarification on “internal coverage criteria” despite receiving more than 33,000 public comments, leaving the boundary between permissible plan restrictions and impermissible service denials still partly unresolved.

Network limits compound the access problem. KFF data shows that Medicare Advantage beneficiaries have access to about half the physicians available to traditional Medicare enrollees in the same area, on average. The oncologist who specializes in a specific cancer subtype may not contract with your plan. The hospital running the relevant clinical trial may not either. Original Medicare paired with a Medigap supplement works differently: any provider that accepts Medicare accepts the plan, and prior authorization for most services does not exist. That is what the higher Medigap premium purchases.

The switch back is the trap

The obvious move after a diagnosis is to leave Medicare Advantage for Original Medicare plus Medigap. It is rarely that simple. A first-time Advantage enrollee has a 12-month trial right to return to Original Medicare with guaranteed-issue Medigap. After that window closes, most states allow Medigap insurers to medically underwrite new applicants, which means they can decline coverage or charge higher premiums. A fresh cancer diagnosis is the worst possible timing for a medically underwritten application. A handful of states, including New York, Connecticut, Massachusetts, and Maine, offer broader continuous or annual guaranteed-issue rights. Most do not.

What to do

If you are the reader in this scenario, three actions matter this week.

• Call the plan and ask for a written list of in-network oncology providers and cancer centers, then confirm whether the treatment center your oncologist recommends is in or out. If it is out, ask whether your plan’s PPO structure covers it at the combined cap or whether you face full charges.
• Check your Medicare Advantage trial-right window. If you enrolled in your first Advantage plan within the last 12 months, you can return to Original Medicare with guaranteed-issue Medigap. Outside that window, verify your state’s specific rules before assuming underwriting closes the door entirely.
• Document every prior authorization request and denial with dates. Under the 2026 federal rules, urgent-care decisions carry a 72-hour clock, and a clear paper trail is what enforces it if a plan drags its feet.

Medicare Advantage can be the right answer for many enrollees. It is simply a different answer in a sick year than in a healthy one, and the gap between those two answers is the part the premium does not advertise.

Editor’s note: This article was updated to include 2026 Medicare Advantage enrollment figures from MedPAC (35.5 million beneficiaries, 55% of all eligible enrollees), the KFF finding that MA networks provide access to roughly half the physicians available in traditional Medicare, and context on the 2026 CMS prior authorization rule (CMS-0057-F) requiring standard decisions within seven days and urgent decisions within 72 hours, along with CMS’s deferral of a key “internal coverage criteria” clarification.

Contact [email protected] for any questions or corrections.